Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDRX-42 vs Sunitinib in GIST After Imatinib
NCT07218926Phase 3Recruiting
- Sponsor
- GSK
- Start
- Dec 2025
- Primary completion
- May 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 19
01
Overview
A Phase 3 trial of IDRX-42 in gastrointestinal stromal tumor (GIST), sponsored by GSK. Started Dec 2025; status: recruiting.
02
Drugs
IDRX-42
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT07218926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218926.